Related Experiment Video

Updated: Jun 19, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Design and synthesis of 6-oxo-1,6-dihydropyridines as CDK5 inhibitors

Matthew R Kaller1, Wenge Zhong, Charles Henley

  • 1Chemistry Research and Discovery, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, United States. mkaller@amgen.com

Bioorganic & Medicinal Chemistry Letters
|October 30, 2009
PubMed

Insights

Researchers optimized novel 6-oxo-1,6-dihydropyridines as potent inhibitors of cyclin-dependent kinase 5 (CDK5). These compounds target CDK5, a key kinase implicated in neurodegenerative disorders due to its abnormal phosphorylation activity.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Medicinal Chemistry

Background:

  • Cyclin-dependent kinase 5 (CDK5) is a crucial serine-threonine protein kinase regulating neuronal development.
  • Aberrant CDK5 activity, particularly in association with p25, contributes to the pathology of neurodegenerative disorders through abnormal substrate phosphorylation.

Purpose of the Study:

  • To design and optimize novel potent inhibitors targeting CDK5.
  • To explore the potential of 6-oxo-1,6-dihydropyridine derivatives as therapeutic agents for CDK5-related conditions.

Main Methods:

  • Utilized active site homology modeling to guide inhibitor design.
  • Leveraged existing structure-activity relationship (SAR) data for lead optimization.
  • Synthesized and evaluated a series of 6-oxo-1,6-dihydropyridine compounds for CDK5 inhibitory activity.

Main Results:

  • Identified and optimized a series of 6-oxo-1,6-dihydropyridine compounds exhibiting potent CDK5 inhibition.
  • Demonstrated the structure-activity relationships guiding the optimization process.
  • Established the potential of this chemical scaffold for developing targeted CDK5 therapeutics.

Conclusions:

  • The 6-oxo-1,6-dihydropyridine scaffold represents a promising chemotype for the development of potent CDK5 inhibitors.
  • Optimized inhibitors hold potential for therapeutic intervention in neurodegenerative diseases linked to aberrant CDK5 activity.

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...